Icosema Guide
Novo Nordisk
Complete guide to Icosema. Icosema is Novo Nordisk
Novo Nordisk\'s Fixed-Ratio Insulin Icodec + Semaglutide Combination
Icosema is Novo Nordisk\'s investigational fixed-ratio combination of insulin icodec (a once-weekly basal insulin) and semaglutide (a GLP-1 receptor agonist). By combining both in a single weekly injection, it aims to simplify diabetes management while providing the metabolic benefits of GLP-1 therapy alongside insulin\'s glucose-lowering power. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Icosema?
Icosema is Novo Nordisk\'s investigational fixed-ratio combination of insulin icodec (a once-weekly basal insulin) and semaglutide (a GLP-1 receptor agonist). By combining both in a single weekly injection, it aims to simplify diabetes management while providing the metabolic benefits of GLP-1 therapy alongside insulin\'s glucose-lowering power.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
Clinical Data
Multiple Phase 3 trials (COMBINE program) are evaluating Icosema in Type 2 diabetes populations.
Side Effects
Vital Protocol FAQs
Guide FAQs
Complete guide to Icosema. Icosema is Novo Nordisk
Yes. Shotlee supports tracking Icosema doses, side effects, and health metrics. It is free to use.
Track Your Icosema Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.